Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, 100730, China.
Department of Obstetrics and Gynecology, China-Japan Friendship Hospital, Beijing, 100029, China.
Cancer Gene Ther. 2021 Dec;28(12):1353-1364. doi: 10.1038/s41417-020-00283-4. Epub 2021 Jan 4.
The association between human papillomavirus (HPV) integration and relevant genomic changes in uterine cervical adenocarcinoma is poorly understood. This study is to depict the genomic mutational landscape in a cohort of 20 patients. HPV+ and HPV- groups were defined as patients with and without HPV integration in the host genome. The genetic changes between these two groups were described and compared by whole-genome sequencing (WGS) and whole-exome sequencing (WES). WGS identified 2916 copy number variations and 743 structural variations. WES identified 6113 somatic mutations, with a mutational burden of 2.4 mutations/Mb. Six genes were predicted as driver genes: PIK3CA, KRAS, TRAPPC12, NDN, GOLGA6L4 and BAIAP3. PIK3CA, NDN, GOLGA6L4, and BAIAP3 were recognized as significantly mutated genes (SMGs). HPV was detected in 95% (19/20) of patients with cervical adenocarcinoma, 7 of whom (36.8%) had HPV integration (HPV+ group). In total, 1036 genes with somatic mutations were confirmed in the HPV+ group, while 289 genes with somatic mutations were confirmed in the group without HPV integration (HPV- group); only 2.1% were shared between the two groups. In the HPV+ group, GOLGA6L4 and BAIAP3 were confirmed as SMGs, while PIK3CA, NDN, KRAS, FUT1, and GOLGA6L64 were identified in the HPV- group. ZDHHC3, PKD1P1, and TGIF2 showed copy number amplifications after HPV integration. In addition, the HPV+ group had significantly more neoantigens. HPV integration rather than HPV infection results in different genomic changes in cervical adenocarcinoma.
人乳头瘤病毒(HPV)整合与子宫颈腺癌相关的基因组变化之间的关联尚未完全阐明。本研究旨在描述 20 例患者队列的基因组突变景观。HPV+和 HPV-组定义为患者在宿主基因组中是否存在 HPV 整合。通过全基因组测序(WGS)和全外显子组测序(WES)描述和比较这两组之间的遗传变化。WGS 鉴定出 2916 个拷贝数变异和 743 个结构变异。WES 鉴定出 6113 个体细胞突变,突变负担为 2.4 个突变/Mb。预测了 6 个基因作为驱动基因:PIK3CA、KRAS、TRAPPC12、NDN、GOLGA6L4 和 BAIAP3。PIK3CA、NDN、GOLGA6L4 和 BAIAP3 被认为是显著突变基因(SMGs)。95%(19/20)的宫颈癌患者检测到 HPV,其中 7 例(36.8%)有 HPV 整合(HPV+组)。总共在 HPV+组中确认了 1036 个具有体细胞突变的基因,而在没有 HPV 整合的组(HPV-组)中确认了 289 个具有体细胞突变的基因;两组之间只有 2.1%的基因共享。在 HPV+组中,GOLGA6L4 和 BAIAP3 被确认为 SMGs,而 PIK3CA、NDN、KRAS、FUT1 和 GOLGA6L64 在 HPV-组中被鉴定。HPV 整合后,ZDHHC3、PKD1P1 和 TGIF2 显示出拷贝数扩增。此外,HPV+组具有更多的新抗原。HPV 整合而不是 HPV 感染导致宫颈癌中不同的基因组变化。